Literature DB >> 11263754

Neuroscience research in AIDS.

D M Rausch1, E S Stover.   

Abstract

1. The human immunodeficiency virus invades the central nervous system early after infection where it later gives rise to cognitive, motor, and behavioral manifestations in children and adults. 2. Ranging from mild impairments to frank dementia, CNS manifestations can be diagnosed and measured with standard neuropsychological test batteries. 3. Great strides have been made with treatment: CNS manifestations are treatable, as are depression, psychosis, and delirium which sometimes accompany HIV disease at different stages. 4. With startling advances in antiretroviral therapy and lower mortality, patients face a constellation of new concerns stemming from HIV's transformation to a more chronic disease. 5. There are many compelling research directions ahead, including the psychosocial impact of living with HIV as a chronic disease, the development of medications expressly targeted to the CNS, and basic research on neuropathogenesis, including trafficking of virus into the CNS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11263754     DOI: 10.1016/s0278-5846(00)00154-8

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  10 in total

1.  Whole brain diffusion tensor imaging in HIV-associated cognitive impairment.

Authors:  Ann B Ragin; Pippa Storey; Bruce A Cohen; Leon G Epstein; Robert R Edelman
Journal:  AJNR Am J Neuroradiol       Date:  2004-02       Impact factor: 3.825

2.  Psychotropic medication use in human immunodeficiency virus-infected youth receiving treatment at a single institution.

Authors:  Lori Wiener; Haven Battles; Celia Ryder; Maryland Pao
Journal:  J Child Adolesc Psychopharmacol       Date:  2006-12       Impact factor: 2.576

Review 3.  Neuropsychological consequences of HIV and substance abuse: a literature review and implications for treatment and future research.

Authors:  Lisa R Norman; Michael Basso; Anil Kumar; Robert Malow
Journal:  Curr Drug Abuse Rev       Date:  2009-05

4.  Critical implication of the (70-96) domain of human immunodeficiency virus type 1 Vpr protein in apoptosis of primary rat cortical and striatal neurons.

Authors:  Emmanuelle N Sabbah; Bernard P Roques
Journal:  J Neurovirol       Date:  2005-12       Impact factor: 2.643

5.  The impact of neuropsychological functioning on adherence to HAART in HIV-infected substance abuse patients.

Authors:  Allison J Applebaum; Laura C Reilly; Jeffrey S Gonzalez; Mark A Richardson; Catherine L Leveroni; Steven A Safren
Journal:  AIDS Patient Care STDS       Date:  2009-06       Impact factor: 5.078

6.  Adherence to antiretroviral medication in older adults living with HIV/AIDS: a comparison of alternative models.

Authors:  Christopher J Johnson; Timothy G Heckman; Nathan B Hansen; Arlene Kochman; Kathleen J Sikkema
Journal:  AIDS Care       Date:  2009-05

Review 7.  An Update of the Review of Neuropsychological Consequences of HIV and Substance Abuse: A Literature Review and Implications for Treatment and Future Research.

Authors:  Lisa R Norman; Michael Basso
Journal:  Curr Drug Abuse Rev       Date:  2015

8.  Contributors to neuropsychological impairment in HIV-infected and HIV-uninfected opiate-dependent patients.

Authors:  Allison J Applebaum; Michael W Otto; Mark A Richardson; Steven A Safren
Journal:  J Clin Exp Neuropsychol       Date:  2010-11-04       Impact factor: 2.475

9.  [Human immunodeficiency virus-associated tuberculous meningoencephalitis causing abnormal behaviour in a prisoner].

Authors:  K-D Herta; M Sturzenegger; M Berkhoff
Journal:  Nervenarzt       Date:  2005-01       Impact factor: 1.214

10.  Dominican Children with HIV not Receiving Antiretrovirals: Massage Therapy Influences their Behavior and Development.

Authors:  Maria Hernandez-Reif; Gail Shor-Posner; Jeannette Baez; Solange Soto; Rosangela Mendoza; Raquel Castillo; Noaris Quintero; Eddy Perez; Guoyan Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2008-09       Impact factor: 2.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.